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A 28-year-oldmale-appearing patient comes into Dr. Miller’s der-
matology clinic for the ﬁrst time. The patient reveals that he is here
for the evaluation of severe acne. Dr. Miller soon learns that the pa-
tient is a transgender man and has been receiving hormone replace-
ment therapy for the past year. He is on a regimen of weekly
self-administered 100 mg intramuscular testosterone enthanate in-
jections, and he has had nomenses since shortly after beginning tes-
tosterone. His testosterone levels have remained in a normal male
range. The patient is not on any other medications and has not had
any procedural interventions for his transition. He is sexually active
with a female partner. He has had his gendermarkers legally changed
to male on his driver’s license and in his medical record. After a long
history of moderate acne, the patient states that his acne became
severe shortly after initiating testosterone. Dr. Miller examines him
and ﬁnds severe nodulocystic acne with areas of postinﬂammatory
hyperpigmentation and scarring distributed over his face and back.
The patient has been on a regimen of a topical retinoid and oral doxy-
cycline for the past 3monthswithout any relief and is requesting oral
isotretinoin. Dr. Miller is unsure of how to proceed because the
patient’s acne could possibly be improved if he stops taking his tes-c. on behalf of Women's Dermattosterone injections. She is also unsure of what sex to assign the pa-
tient when enrolling in iPLEDGE.
Dr. Miller should:
A. Agree to start the patient on oral isotretinoin only if the patient
stops taking supplemental testosterone and his severe acne
remains.
B. Agree to start the patient on oral isotretinoin and register the pa-
tient as a female of childbearing potential.
C. Agree to start the patient on oral isotretinoin and register the pa-
tient as a female of nonchildbearing potential.
D. Agree to start the patient on oral isotretinoin and register the pa-
tient as a male.Discussion
Transgendermedicine is an emergingﬁeld of health care that con-
tinues to make ground in public awareness, especially in the context
of the recent media spotlight on many transgender individuals, such
as the actress Laverne Cox and the athlete Caitlyn Jenner. Despite
these gains, muchwork needs to be accomplished in order to provide
transgender people with adequate access to care. Reports have
shown that almost 90% of transgender patients feel that their health
care professionals lack adequate knowledge and sensitivity to their
medical needs. Additionally, a majority of patients feel that they
have been discriminated against in the health care setting becauseologic Society. This is an open access article under the CC BY-NC-ND license (http://
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transgender patients, physicians will be faced with many unforeseen
challenges, one of which is presented in our case.
There are several ethical points to consider in this case scenario.
With regard to the patient, the physician has an obligation to honor
the patient’s gender transition but also an obligation to act in a
nonmaleﬁcent way. iPLEDGE providers also have a contractual obli-
gation with the iPLEDGE program and must honor this. If a physician
decides to register a transgender male patient as female, the physi-
cian must determine whether the patient ﬁts the deﬁnition of a fe-
male of childbearing potential, which iPLEDGE deﬁnes as “a
nonmenopausal female who has not had a hysterectomy, bilateral
oophorectomy, or medically documented ovarian failure” (iPLEDGE
program, 2015). iPLEDGE recommends a particular panel of blood
work for patients under age 54 to support a ﬁnding of hormonal de-
ﬁciency (iPLEDGE program, 2015). Yet, the results they stipulate only
apply to women with premature ovarian failure. These tests would
have different results in a transgender man on testosterone therapy
and could not reliably be used to determine if he is anovulatory. How-
ever, the potential for pregnancy for female-to-male transgender pa-
tients on testosterone is extremely low, as testosterone is known to
suppress ovulation, in addition to impairing fertility in other ways
(Hembree et al., 2009).
Currently, there is not a transgender male category in iPLEDGE,
though perhaps an adjustment of the current categorizations is need-
ed to more accurately serve transgender patients, while respecting
iPLEDGE (Katz, 2016). We present the analysis of the case scenario
later in the context of the current gender system in order to guide cli-
nicians under present restrictions.
How should Dr. Miller proceed in order to respect the patient’s
wishes and transgender status yet honor her contractual obligation
to iPLEDGE?
Analysis of case scenario
In option 1, the physician correctly identiﬁes the patient’s acne as
most likely exacerbated by supplemental testosterone. The clinician
provides the patient the option of initiating isotretinoin therapy but
at the expense of discontinuing hormone replacement therapy.
Some physicians might assume that this option would adhere to
the tenet of nonmaleﬁcence by avoiding treating a medication-
exacerbated problem with another medication, which could cause
potential harm to the patient. However, nonmaleﬁcence is also im-
portant in the sense of avoiding psychological harm to the patient
caused by stopping testosterone. Furthermore, since gender identity
is a durable biological phenomenon (Saraswat et al., 2015), supple-
mental testosterone should be viewed as a necessary, vital medica-
tion for transgender men. Reports have shown that helping
transgender patients transition, such as through hormone replace-
ment therapy, dramatically improves quality of life and can signiﬁ-
cantly reduce attempts of suicide (Gorin-Lazard et al., 2012;
Lambda Legal, 2010). Removing testosterone therefore would disre-
spect the dignity of the patient’s medical needs to maintain his tran-
sition. Additionally, the patient should have the autonomy to choose
to both stay on testosterone and begin isotretinoin, if the patient is
well-informed of the risks and beneﬁts of taking bothmedications si-
multaneously. Finally, under the tenet of beneﬁcence, it is in the pa-
tient’s best interest to both aggressively treat his acne and to
continue hormone therapy.
For options 2, 3, and 4, there are two points to consider: the sex to
assign the patient for the purposes of enrolling in iPLEDGE and, if fe-
male, whether to register as childbearing or nonchildbearing poten-
tial. Our patient has not undergone cross-gender genital surgery
and so is still in possession of ovaries and a uterus. In the current sys-
tem, he would need to be registered as female. Here the patient’sdignity to be registered as amale is outweighed byhis potential to be-
come pregnant while on isotretinoin. While the patient is likely an-
ovulatory as a result of testosterone, there is no way to be certain of
this, and if he were to stop taking testosterone, his fertility could re-
turn. For these reasons, the tenet of nonmaleﬁcence dictates that
he should be registered as a female of childbearing potential in
order to best protect against potential pregnancy. Thus, the cur-
rent gender categorization in iPLEDGE necessitates an empathic
discussion with the patient regarding system requirements and
limitations, which can help preserve the dignity of the patient’s
identiﬁed gender.
The patient in our case scenario could claim abstinence as one of
his contraceptive methods if he refrains from having intercourse
with men. However, if he does begin to have intercourse with men
while receiving treatment, an additional form of contraception
should be considered since we are currently not equipped to deter-
mine whether a transgender man on testosterone therapy has zero
potential to ovulate. This may compromise the patient’s dignity at
the expense of the tenet of beneﬁcence, which dictates that the best
interest of the patient is to legally adhere to iPLEDGE in order to be
able to treat his severe acne with isotretinoin. In the future, though,
if testosterone therapy is determined to have comparable pregnancy
prevention effects to that of current hormonal contraception, testos-
terone therapy could be considered amethod of contraception. Final-
ly, the patientwill also need to undergomonthly pregnancy tests, but
this can be performed through blood tests, along with his other rou-
tine isotretinoin-related blood work in order to respect the patient’s
dignity and to minimize the potential negative psychological effects
associated with taking a urine pregnancy test.
Conclusion
Transgender individuals have unique medical needs that will
surely lead to many unforeseen medical and ethical dilemmas as
these patients become more visible in the increasingly diverse medi-
cal environment.Many of these dilemmas center around the patient’s
stage with regard to his or her transition, such as is the case for our
patient. Physiciansmust considerwhether the patient has undergone
transgender genital surgery, the sex of the patient’s partner with re-
gard to contraceptive recommendations, and the patient’s hormone
replacement therapy regimen.
Despite the aforementioned complexities, transgender patients’
gender identities and autonomy to transition should be respected.
For our patient, even though his current complaint is presumably ex-
acerbated by a medication for his transition, there is no need for Dr.
Miller to take him off testosterone. It is acceptable to start him on
oral isotretinoin. Dr. Miller must register the patient as female of
childbearing potential based on the current gender categorization
scheme in iPLEDGE.
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